• The U.S. federal budget process depends heavily on objective assessments of both federal spending and tax receipts under alternative scenarios.
• Typically, policymakers want to know two things: what will happen under current law or baseline, and what will happen if there were a change in the law.
• Cost estimating can be a straightforward exercise, or an extremely complex one.
The Crucial Role of the Estimators in the Legislative Budget Process
• Two primary agencies project future spending -Office of the Actuary (OACT) at the Centers for Medicare and Medicaid Services
• OACT responsible for projecting future spending for Medicare -Congressional Budget Office (CBO)
• Nonpartisan body that scores new legislation
• CBO only includes data that meets their professional standards for scientific rigor.
-By their nature short-term costs are almost always more predictable than long-term saving.
Developing Federal Cost Estimates
• CBO also works in a required scoring window -Currently 10 years -Used to be 5 years
• Modeling to Predict Effects of Legislation.
-Traditionally provider and payer focused modeling, not disease-based.
-Clinical information is typically not included
• Diabetes is an excellent chronic condition for demonstrating potential contribution clinical information can make to cost estimating.
• Natural history of diabetes has been assessed and modeled extensively over a decade.
-The baseline progression of major complications are well documented.
-The effect of treatment interventions are generally well understood (but evolving).
-Multiple scientific organizations have created diabetes models (NIH, CDC, UK, and European).
Potential Implications of Diabetes Simulation Models Diabetes Trials and Models
• Publication of groundbreaking trials has been followed by model building • Models designed to simulate the natural history of major diabetes complications
• Models regularly compared during the Mount Hood Challenge
The Budget Window, Disease Progression, and Effect of Treatment #1 Where appropriate, include the best epidemiologic data and modeling in baseline and intervention estimates:
-Allow the modeling of obesity trends and their interaction with chronic illness, like diabetes.
-Incorporation of consensus lessons learned from clinical trials.
-Challenge to the epidemiological community be sure the data and trials meet rigorous standards for inclusion in the policy debate.
Possible Enhancements
#2 In certain instances, look beyond the traditional 10-year budget window, if the data indicates a better understanding for policymakers.
-For most proposals a 10-year window is appropriate, but if theres a well established natural history of the disease exceptions should be possible.
-Cuts both ways CBO may find that for many proposal a longer window would show ballooning spending in the out years. 
Policy Projections Policy Projections
• Modeled a prototypical diabetes treatment improvement intervention that is similar to current well-designed disease management programs.
• Intensify the treatment of individuals with prevalent and incident diabetes aiming to improve • Discoveries regarding natural history of diseases and their treatments could be leveraged by cost estimators 37
U.S. Budget Process Implications
• Current congressional budget procedures are already moving toward a longer-term focus:
-CBO is issuing more long-term estimates for health care entitlements -The Senate adopted a new rule which will require CBO to produce long-term cost estimates under certain circumstances
• Our focus:
-Introducing epidemiological modeling as a viable supplement to current cost estimating approaches -Extension of the budget window as appropriate, especially in the context of policymaking for chronic illnesses with long time horizons -Where there is clear and convincing data, allowing improved chronic illness cost estimating to influence budget enforcement within the current ten-year window
